Back to Massachusetts

H193 • 2025

An Act to improve warning labels on THC products

An Act to improve warning labels on THC products

Active

The official status still shows this bill as active or still awaiting another formal step.

Sponsor
Marcus S. Vaughn
Last action
2026-05-11
Official status
Accompanied a study order, see H5396 (under House Rule 27)
Effective date
Not listed

Plain English Breakdown

Using official source text because the generated explanation was unavailable or could not be confirmed against the official bill text.

An Act to improve warning labels on THC products

An Act to improve warning labels on THC products By Representative Vaughn of Wrentham, a petition (accompanied by bill, House, No.

What This Bill Does

  • An Act to improve warning labels on THC products By Representative Vaughn of Wrentham, a petition (accompanied by bill, House, No.
  • 193) of Marcus S.
  • Vaughn relative to warning labels on products containing cannabis.
  • Cannabis Policy.

Limits and Unknowns

  • This entry is temporarily using official source text because the generated explanation could not be confirmed against the official bill text during the last sync.

Bill History

  1. 2026-05-11 House

    Accompanied a study order, see H5396 (under House Rule 27)

  2. 2025-05-01 Joint

    Hearing scheduled for 05/07/2025 from 10:30 AM-01:00 PM in B-1

  3. 2025-02-27 House

    Referred to the committee on Cannabis Policy

  4. 2025-02-27 Senate

    Senate concurred

  5. House

    Reported by committee to Clerk’s Office for processing, will accompany a study order

Official Summary Text

An Act to improve warning labels on THC products
By Representative Vaughn of Wrentham, a petition (accompanied by bill, House, No. 193) of Marcus S. Vaughn relative to warning labels on products containing cannabis. Cannabis Policy.

Current Bill Text

Read the full stored bill text
×

Bill H.193

SECTION 1. Subsection (a1/2) of section 4 of chapter 94G of the General Laws is hereby amended by striking clause (xxvi) and inserting in place thereof the following:

(xxvi) requirements for the labeling of a package containing marijuana or marijuana products that shall, at a minimum, include: (1) a symbol or easily recognizable mark issued by the commission that indicates the package contains marijuana or a marijuana product; (2) a symbol or other easily recognizable mark issued by the commission on the package indicating to children that the product is harmful to children; (3) the name and contact information of the marijuana cultivator or the marijuana product manufacturer who produced the marijuana or marijuana product; (4) the results of sampling, testing and analysis conducted by a licensed independent testing laboratory; (5) a seal certifying the marijuana meets such testing standards; (6) a unique batch number identifying the production batch associated with manufacturing, processing, and cultivating; (7) a list of ingredients and possible allergens; (8) in bold, the amount of delta-nine-tetrahydrocannabinol (Δ9–THC) in the package and in each serving of a marijuana product as expressed in absolute terms and as a percentage of volume; (9) the number of servings in a package if there are multiple servings; (10) a use-by date, if applicable; and (11) the following statement, including capitalization: ''This product has not been analyzed or approved by the FDA. There is limited information on the side effects of using this product, and there may be associated health risks. Marijuana use during pregnancy and breast-feeding may pose potential harms. It is against the law to drive or operate machinery when under the influence of this product. KEEP THIS PRODUCT AWAY FROM CHILDREN.''; and (12) comprehensive prominent rotating health warnings, based on the best available research on what constitutes effective warnings for transmitting knowledge and achieving behavior change from tobacco and cannabis warning research, including pictorial warnings if supported.

These regulations shall be periodically updated based on emerging science on cannabis and on warning communication best practices. These warnings must also include the increased risk of cannabinoid hyperemesis syndrome, cannabis use disorder, mood disorders, psychosis described as paranoia, hallucinations, delusions, schizophrenia , and suicidal thoughts with use of THC-containing marijuana products, especially when initiated young, used frequently, and/or with use of products containing more than 10% THC.

The information contained in this website is for general information purposes only. The General Court provides this information as a public service and while we endeavor to keep the data accurate and current to the best of our ability, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.

Close